3 results
Approved WMORecruiting
Subjects randomized to the placebo treatment are unlikely to benefit from the study. However, OAB is not a life-threatening disease and it is not expected that a 12 to 15 week exposure to placebo treatment will have a negative impact on disease…
Approved WMORecruiting
To evaluate safety and the effect of isolated limb perfusion together with nivolumab as a way to increase efficacy and give further insights in early immunological mechanisms. In the first phase Ib part, 20 patients will be enrolled and followed for…
Approved WMORecruiting
The aim of the current study is to assess the potential time- and cost-savings of fluoroscopically aided reductions of dislocated DRFs in adult patients.